Please use this identifier to cite or link to this item:
Title: The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study.
Author: Norman, Gary L.
Reig, Anna
Viñas, Odette
Mahler, Michael
Wunsch, Ewa
Milkiewicz, Piotr
Swain, Mark G.
Mason, Andrew
Stinton, Laura M.
Aparicio, Maria Belen
Aldegunde, Maria Jose
Fritzler, Marvin J.
Parés Darnaculleta, Albert
Keywords: Immunoglobulines
Issue Date: 3-Apr-2019
Publisher: Frontiers Media
Abstract: Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is present worldwide. Autoantibodies, in particular anti-mitochondrial antibodies (AMA) detected by indirect immunofluorescence assays or newer solid phase immunoassays can detect most, but not all individuals with PBC. Detection of antibodies to the anti-nuclear antigens sp100 and gp210 can identify additional PBC patients, but some seronegative patients remain, often resulting in delayed diagnosis and treatment. Antibodies to kelch-like 12 (KLHL12) and hexokinase 1 (HK-1) were recently identified as new biomarkers for PBC and notably identify patients who are negative for conventional autoantibodies. To become globally adopted, it is important to validate these new biomarkers in different geographic areas. In the present study we evaluated the prevalence of anti-KLHL12 (measured by a KLHL12-derived peptide referred to as KL-p) and anti-HK-1 antibodies by ELISA at five sites within Europe and North America and demonstrated the presence of these antibodies in patients with PBC in all geographies.
Note: Reproducció del document publicat a:
It is part of: Frontiers in Immunology, 2019, vol. 10, p. 662
Related resource:
ISSN: 1664-3224
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
694853.pdf529.75 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons